GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (BUE:AMGN) » Definitions » Buyback Yield %

Amgen (BUE:AMGN) Buyback Yield %

: 0.00 (As of Today)
View and export this data going back to . Start your Free Trial

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Amgen's current buyback yield was 0.00%.


Amgen Buyback Yield % Historical Data

The historical data trend for Amgen's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Buyback Yield %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 157.14 75.12 98.50 112.43 -

Amgen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Buyback Yield % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Drug Manufacturers - General subindustry, Amgen's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amgen Buyback Yield % Distribution

For the Drug Manufacturers industry and Healthcare sector, Amgen's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Amgen's Buyback Yield % falls into.



Amgen Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Amgen's Buyback Yield for the fiscal year that ended in Dec. 2023 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0) / 2998240
=0.00%

Amgen's annualized Buyback Yield for the quarter that ended in Dec. 2023 is calculated as

Buyback Yield=Net Issuance of Stock(Annualized) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) * Annualized Factor / Market Cap
=- (0 + 0) * 4 / 2998240
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Dec. 2023) data.


Amgen Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Amgen's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Amgen (BUE:AMGN) Business Description

Address
One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Amgen (BUE:AMGN) Headlines

From GuruFocus

Amgen Inc at Evercore ISI HealthCONx Conference Transcript

By GuruFocus Research 01-22-2024

Q1 2023 Amgen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q4 2022 Amgen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Amgen Inc at Citi Global Healthcare Conference Transcript

By GuruFocus Research 01-22-2024

Amgen Inc Corporate Call Transcript

By GuruFocus Research 01-22-2024

Amgen Inc at Citi BioPharma Conference Transcript

By GuruFocus Research 01-22-2024